Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates

Journal of the American Academy of Dermatology
Volume 47, n° 2PB
pages 193-195 (août 2002)
Doi : 10.1067/mjd.2002.109255
Thalidomide therapy for cicatricial pemphigoid

Daihung Jay Duong, MDa, Richard T. Moxley, MDa, Robert M. Kellman, MDb, Stephanie H. Pincus, MDc, Anthony A. Gaspari, MDc
From the Departments of Neurology and Otolaryngology,a State University of New York at Syracuse, Department of Dermatology, State University of New York at Buffalo,b and Departments of Dermatology and Microbiology/Immunology and the Cancer Center, University of Rochester School of Medicine and Dentistry.c 


Cicatricial pemphigoid is a chronic, presumed autoimmune, blistering disease of the mucous membranes and occasionally of the skin. The characteristic feature is scarring at the sites of healing. We report the use of thalidomide as a therapeutic agent to control previously resistant disease. (J Am Acad Dermatol 2002;47:S193-5).

The full text of this article is available in PDF format.

 Supported by NIH grant 1R01AH/OH4108-03.

Top of the page

© 2002  The American Academy of Dermatology, Inc.@@#104156@@